A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies

peer-reviewed · mAbs · 2022

peer-reviewed · mAbs · 2022. Sebastiaan C. de Graaf et al. A key step in therapeutic and endogenous humoral antibody characterization is identifying the amino acid…
Date 2022-12-31
Type peer-reviewed
Venue mAbs
Publisher Informa UK Limited
Contribution review
DOI 10.1080/19420862.2022.2079449
Citations (OpenAlex) 48

Abstract

A key step in therapeutic and endogenous humoral antibody characterization is identifying the amino acid sequence. So far, this task has been mainly tackled through sequencing of B-cell receptor (BCR) repertoires at the nucleotide level. Mass spectrometry (MS) has emerged as an alternative tool for obtaining sequence information directly at the - most relevant - protein level. Although several MS methods are now well established, analysis of recombinant and endogenous antibodies comes with a specific set of challenges, requiring approaches beyond the conventional proteomics workflows. Here, we review the challenges in MS-based sequencing of both recombinant as well as endogenous humoral antibodies and outline state-of-the-art methods attempting to overcome these obstacles. We highlight recent examples and discuss remaining challenges. We foresee a great future for these approaches making de novo antibody sequencing and discovery by MS-based techniques feasible, even for complex clinical samples from endogenous sources such as serum and other liquid biopsies.

Authors

  1. Sebastiaan C. de Graaf
  2. Max Hoek · Netherlands Proteomics Centre, Utrecht University
  3. Sem Tamara · Netherlands Proteomics Centre, Utrecht University
  4. Albert J. R. Heck · Center for Biomedical Genetics, Netherlands Proteomics Centre, Utrecht University

Methods and tools

  • Endogenous antibody de novo sequencing (perspective): Perspective on reading antibody sequences at the protein level rather than from B-cell receptor repertoires at the nucleotide level, surveying what mass spectrometry can already do for therapeutic antibodies and what endogenous, polyclonal ones still demand.

Cites (14)

Cited by (5)

Seen in the charts

Back to the full map

Back to top